CYTR - CytRx Corporation

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
0.6168
+0.0268 (+4.54%)
As of 3:19PM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.5900
Open0.6050
Bid0.6150 x 2200
Ask0.6200 x 800
Day's Range0.5900 - 0.6350
52 Week Range0.3300 - 2.3500
Volume224,202
Avg. Volume175,353
Market Cap20.748M
Beta (3Y Monthly)1.71
PE Ratio (TTM)N/A
EPS (TTM)-0.5030
Earnings DateNov 6, 2018 - Nov 12, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial
    PR Newswire2 days ago

    CytRx Corporation Highlights Aldoxorubicin's Inclusion In New NantCell Inc. Colorectal Cancer Clinical Trial

    LOS ANGELES, Jan. 14, 2019 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with relapsed or refractory colorectal cancer (CRC) who have been previously treated with standard of care (SOC) therapy.  This is the fourth trial conducted by NantCell which will investigate high-affinity natural killer (haNK) cell therapy in combination with anti-cancer agents, including aldoxorubicin, in certain high unmet need cancer indications.

  • CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic
    PR Newswire26 days ago

    CytRx Corporation Announces Conclusion of Pre-Clinical Phase for Its Albumin Binding Ultra High Potency LADR™ Drug Candidates and Accompanying Companion Diagnostic

    LOS ANGELES, Dec. 21, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that its private, wholly-owned subsidiary Centurion BioPharma Corporation (the Company) has concluded the pre-clinical phase of its development for its albumin binding ultra high potency LADR™ (Linker Activated Drug Release) drug candidates, LADR-7, LADR-8, LADR-9 and LADR-10, and for its unique albumin companion diagnostic (ACDx).  As a result of completing this work, operations taking place at the pre-clinical laboratory located in Freiburg, Germany will no longer be needed. The LADR™ platform combines Centurion's proprietary linker chemistry with albumin biology to create anti-cancer molecules that the Company believes will deliver highly potent agents directly to the tumor, while avoiding unacceptable systemic toxicity.  The pre-clinical laboratory synthesized and evaluated over 75 rationally-designed drug conjugates across two distinct classes of compounds, the auristatins and maytansinoids.

  • CytRx Corporation to Present at the 11th Annual LD Micro Main Event
    PR Newswire2 months ago

    CytRx Corporation to Present at the 11th Annual LD Micro Main Event

    CytRx's wholly owned subsidiary, Centurion BioPharma Corporation, is focused on the development of personalized medicine that will transform solid tumor treatment. This transformational strategy combines a portfolio of novel, anti-cancer drug candidates that employ LADR™ (Linker Activated Drug Release) technology, a discovery engine designed to leverage Centurion's expertise in albumin biology and linker technology for the development of a new class of breakthrough anti-cancer therapies with a unique albumin companion diagnostic (ACDx) that can help identify patients who are most likely to benefit from treatment with the LADR™-derived therapies. This technology allows for the delivery of higher doses of drug directly to the tumor, while avoiding much of the off-target toxicity observed with the parent molecules.  Centurion BioPharma Corporation's website is www.centurionbiopharma.com.

  • GlobeNewswire2 months ago

    Report: Exploring Fundamental Drivers Behind Graphic Packaging Holding, QEP Resources, Inogen, CytRx, Voyager Therapeutics, and Daily Journal Corp. (S.C.) — New Horizons, Emerging Trends, and Upcoming Developments

    NEW YORK, Nov. 23, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CYTR earnings conference call or presentation 2-Nov-18 3:00pm GMT

    Q3 2018 CytRx Corp Earnings Call

  • Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems
    Zacks2 months ago

    Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems

    Zacks.com featured highlights include: Ralph Lauren, Estee Lauder, GMS, CytRx and T2 Biosystems

  • Bet on Rising P/E Investing With These 5 Top-Ranked Stocks
    Zacks2 months ago

    Bet on Rising P/E Investing With These 5 Top-Ranked Stocks

    Want to try an out-of-the-box approach? Tap five stocks with increasing P/E ratios.

  • CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting
    PR Newswire2 months ago

    CytRx Corporation Highlights NantCell Inc's Clinical Data with Aldoxorubicin Presented at the Society for Immunotherapy of Cancer's 33rd Annual Meeting

    Aldoxorubicin Is Part of the NANT Cancer Vaccine Combinations Which Include Immunotherapy and Cell-based Therapy Early Safely Data Are Encouraging and There Are Emerging Positive Signals of Clinical Activity ...

  • Associated Press2 months ago

    CytRx: 3Q Earnings Snapshot

    On a per-share basis, the Los Angeles-based company said it had a loss of 10 cents. The cancer drug developer posted revenue of $250,000 in the period. The company's shares closed at 75 cents. A year ago, ...

  • CytRx Corporation Reports Third Quarter 2018 Financial Results
    PR Newswire2 months ago

    CytRx Corporation Reports Third Quarter 2018 Financial Results

    Quarter Marked by Centurion's Filing of a Provisional Patent for Breakthrough Personalized Medicine Companion Diagnostic to Accompany LADR Assets Improved Finances and Capital Structure Through Expiration ...

  • Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline
    PR Newswire3 months ago

    Key Emerging Oncology Trends By Big Pharma Strengthen CytRx's Rationally Designed, Targeted Therapies Pipeline

    LOS ANGELES, Oct. 31, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that key emerging cancer treatment trends by Big Pharma, including combining immunotherapy with effective chemotherapy regimens, are resulting in significant advancements for the treatment of patients with high unmet medical need types of cancer.  CytRx, along with its wholly owned subsidiary Centurion Biopharma, believe these trends strengthen and enhance the value proposition for their rationally designed albumin binding ultra-high potency anti-cancer agents.

  • CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018
    PR Newswire3 months ago

    CytRx to Hold Third Quarter 2018 Financial Results Conference Call and Webcast on Friday, November 2, 2018

    LOS ANGELES , Oct. 29, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will report financial ...

  • Thomson Reuters StreetEvents4 months ago

    Edited Transcript of CYTR earnings conference call or presentation 6-Aug-18 3:00pm GMT

    Q2 2018 CytRx Corp Earnings Call

  • CytRx Corporation to Present at the 2018 MicroCap Conference
    PR Newswire4 months ago

    CytRx Corporation to Present at the 2018 MicroCap Conference

    LOS ANGELES, Sept. 25, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric Curtis, President and Chief Operating Officer, will present at the 2018 MicroCap Conference on Tuesday, October 2, 2018 at 3:00 P.M. Eastern Daylight Time at the Essex House in New York City. The MicroCap Conference is an exclusive event dedicated to connecting small and micro-cap companies with high-level, institutional and retail investors. The MicroCap Conference will highlight the most attractive companies across various sectors.

  • CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S
    PR Newswire4 months ago

    CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S

    LOS ANGELES, Sept. 13, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced it has received a milestone payment of $250,000 (USD) from Orphazyme A/S (ORPHA.CO). The payment is a result of Orphazyme dosing the first patient in their Phase 3 clinical trial evaluating arimoclomol in patients with amyotrophic lateral sclerosis (ALS).

  • CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018
    PR Newswire5 months ago

    CytRx Corporation to Present at the H.C. Wainwright & Co. 20th Annual Global Investment Conference in New York City September 4-6, 2018

    LOS ANGELES, Aug. 27, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric Curtis, President and Chief Operating Officer, will present at the H.C. Wainwright 20th Annual Global Investment Conference. H.C. Wainwright & Co. LLC is an investment bank dedicated to providing corporate finance, strategic advisory, research, sales and trading, and other related services to public and private growth companies across multiple sectors and regions. At the Conference, more than 250 presenting companies and credentialed investors consisting of portfolio managers, hedge fund managers, and family offices will have the opportunity to engage in one-on-one meetings and networking opportunities.

  • ACCESSWIRE5 months ago

    CytRx Corporation to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 6, 2018 / CytRx Corporation (NASDAQ: CYTR ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 11:00 AM Eastern Time. ...

  • Associated Press5 months ago

    CytRx: 2Q Earnings Snapshot

    The Los Angeles-based company said it had a loss of 10 cents per share. The company's shares closed at $1.15. A year ago, they were trading at $3.78. _____ This story was generated by Automated Insights ...

  • CytRx Corporation Reports Second Quarter 2018 Financial Results
    PR Newswire5 months ago

    CytRx Corporation Reports Second Quarter 2018 Financial Results

    Substantial Reduction in CytRx Cash Burn Rate This Quarter Company to Host Conference Call Today at 11:00 am ET (8:00 am PT) LOS ANGELES , Aug. 6, 2018 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), ...

  • PR Newswire6 months ago

    CytRx Corporation Pays Off Balance of Outstanding Debt

    LOS ANGELES, Aug. 1, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it has made the final scheduled payment under a long-term loan facility agreement with Hercules Technology Growth Capital, Inc. and Hercules Technology III, L.P.  As of, August 1, 2018, the Hercules loan was paid in full. "Our current focus is on securing strategic partnerships for our wholly owned subsidiary Centurion BioPharma Corporation.

  • PR Newswire6 months ago

    CytRx Corporation to Hold Second Quarter 2018 Financial Results Conference Call and Webcast on Monday, August 6, 2018

    LOS ANGELES, July 30, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that it will report financial results for the quarter ended June 30, 2018 on Monday, August 6, 2018. CytRx executives Eric L. Curtis, President and Chief Operating Officer, and John Caloz, Chief Financial Officer, will hold a conference call and webcast beginning at 11:00 a.m. Eastern Time (8:00 a.m. Pacific Time) on that day to discuss the financial results as well as provide an overview of corporate achievements of both CytRx Corporation and Centurion BioPharma Corporation. To access the conference call, dial (+1)844-358-6753 (U.S. and Canada) or (+1)216-562-0397 (international callers) and enter the conference ID number: 5991089.  A live and archived webcast will be available in the News and Events/Events Calendar section of the company's website, www.cytrx.com.

  • PR Newswire6 months ago

    CytRx Announces Centurion BioPharma Corporation's Filing of a Provisional Patent Application

    Breakthrough Personalized Medicine Companion Diagnostic Filed for its Albumin-binding Drug Candidates LOS ANGELES , July 25, 2018 /PRNewswire/ -- CytRx Corporation (Nasdaq: CYTR), a biopharmaceutical research ...

  • PR Newswire6 months ago

    CytRx Corporation Announces Expiration of Outstanding Warrants

    LOS ANGELES, July 23, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced the expiration of warrants for approximately 3.2 million shares of its common stock, effective July 20, 2018. In December 2016, CytRx completed a public offering to its institutional investors of 1.9 million shares of its common stock.

  • PR Newswire6 months ago

    CytRx Corporation to Present at the Singular Research Summer Solstice 2018 Conference

    LOS ANGELES, July 16, 2018 /PRNewswire/ -- CytRx Corporation (CYTR), a biopharmaceutical research and development company specializing in oncology, today announced that Mr. Eric Curtis, CytRx's President and Chief Operating Officer, will present at the Singular Research Summer Solstice 2018 Conference on Thursday, July 19 at 12:00 noon Eastern Daylight Time at Convene-Midtown West in New York, NY. Conference attendees consist of portfolio managers, hedge fund managers, family offices, and leading banking, trading and brokerage firms. CytRx Corporation (CYTR) is a biopharmaceutical company with expertise in discovering and developing new therapeutics to treat patients with cancer. CytRx's most advanced drug conjugate, aldoxorubicin, is an improved version of the widely used anti-cancer drug doxorubicin and has been out-licensed to NantCell, Inc.  CytRx's website is www.cytrx.com.

  • PR Newswire7 months ago

    CytRx Corporation Highlights Aldoxorubicin Included in New NantCell Inc. Triple Negative Breast Cancer Clinical Trial

    LOS ANGELES, June 28, 2018 /PRNewswire/ -- CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today highlighted that aldoxorubicin licensee NantCell, Inc., a private subsidiary of NantWorks, LLC, has dosed the first patient in the Phase 1b portion of a Phase 1b/2 clinical trial for patients with triple negative breast cancer (TNBC). This is the third trial conducted by NantCell which will investigate aldoxorubicin combined with immunotherapy or high-affinity natural killer (haNK) cell therapy in certain high unmet need cancer indications.